Triumvera, co-founded by McMaster's professor Jonathan Bramson, looks to progress its solid tumour therapeutic candidate.

Triumvira Immunologics, a US-based cancer therapeutics developer co-founded by McMaster University faculty, expanded its series A round to $100m yesterday.

The $45m extension featured Leaps by Bayer, the impact corporate venturing arm of pharmaceutical and chemicals group Bayer, Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, B Capital Group, Atem Capital, Myeloma Investment Fund, Northpond Ventures and undisclosed other investors.

Triumvira is working on non-gene edited autologous and allogeneic T cell medications designed to leverage the biology of T cells to treat solid tumours. Its co-founders include Jonathan Bramson, a professor in McMaster University’s Department of Pathology and Molecular Medicine.

The series A proceeds will fund further development of the company’s T cell antigen coupler (TAC) drug candidates. Its lead candidate, TAC01-HER2, is in a phase 1/2 clinical trial for solid tumours in breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers.

The round’s $55m first tranche was…